Replacing Saturated Fats with Unsaturated Fats from Walnuts or Vegetable Oils Lowers Atherogenic Lipoprotein Classes Without Increasing Lipoprotein(a).
Adult
Aged
Cholesterol, HDL
/ blood
Cholesterol, LDL
/ blood
Cross-Over Studies
Diet
Fats, Unsaturated
/ administration & dosage
Fatty Acids
/ administration & dosage
Female
Food Analysis
Gene Expression Regulation
/ drug effects
Humans
Juglans
/ chemistry
Lipoprotein(a)
/ blood
Male
Middle Aged
Overweight
Plant Oils
/ chemistry
Proprotein Convertase 9
/ genetics
PCSK9
cholesterol efflux
lipids
lipoproteins
walnut
Journal
The Journal of nutrition
ISSN: 1541-6100
Titre abrégé: J Nutr
Pays: United States
ID NLM: 0404243
Informations de publication
Date de publication:
01 04 2020
01 04 2020
Historique:
received:
04
08
2019
revised:
01
10
2019
accepted:
26
11
2019
pubmed:
8
1
2020
medline:
15
8
2020
entrez:
8
1
2020
Statut:
ppublish
Résumé
Walnuts have established lipid-/lipoprotein-lowering properties; however, their effect on lipoprotein subclasses has not been investigated. Furthermore, the mechanisms by which walnuts improve lipid/lipoprotein concentrations are incompletely understood. We aimed to examine, as exploratory outcomes of this trial, the effect of replacing SFAs with unsaturated fats from walnuts or vegetable oils on lipoprotein subclasses, cholesterol efflux, and proprotein convertase subtilisin/kexin type 9 (PCSK9). A randomized, crossover, controlled-feeding study was conducted in individuals at risk of cardiovascular disease (CVD) (n = 34; 62% men; mean ± SD age 44 ± 10 y; BMI: 30.1 ± 4.9 kg/m2). After a 2-wk run-in diet (12% SFAs, 7% PUFAs, 12% MUFAs), subjects consumed the following diets, in randomized order, for 6 wk: 1) walnut diet (WD) [57-99 g/d walnuts, 7% SFAs, 16% PUFAs [2.7% α-linolenic acid (ALA)], 9% MUFAs]; 2) walnut fatty acid-matched diet [7% SFAs, 16% PUFAs (2.6% ALA), 9% MUFAs]; and 3) oleic acid replaces ALA diet (ORAD) [7% SFAs, 14% PUFAs (0.4% ALA); 12% MUFAs] (all percentages listed are of total kilocalories ). Serum collected after the run-in (baseline) and each diet period was analyzed for lipoprotein classes and subclasses (vertical auto profile), cholesterol efflux, and PCSK9. Linear mixed models were used for data analysis. Compared with the ORAD, total cholesterol (mean ± SEM -8.9± 2.3 mg/dL; -5.1%; P < 0.001), non-HDL cholesterol (-7.4 ± 2.0 mg/dL; -5.4%; P = 0.001), and LDL cholesterol (-6.9 ± 1.9 mg/dL; -6.5%; P = 0.001) were lower after the WD; no other pairwise differences existed. There were no between-diet differences for HDL-cholesterol or LDL-cholesterol subclasses. Lipoprotein(a) [Lp(a)], cholesterol efflux, and PCSK9 were unchanged after the diets. In individuals at risk of CVD, replacement of SFAs with unsaturated fats from walnuts or vegetable oils improved lipid/lipoprotein classes, including LDL-cholesterol, non-HDL cholesterol, and total cholesterol, without an increase in Lp(a). These improvements were not explained by changes in cholesterol efflux capacity or PCSK9. This trial was registered at clinicaltrials.gov as NCT01235832.
Sections du résumé
BACKGROUND
Walnuts have established lipid-/lipoprotein-lowering properties; however, their effect on lipoprotein subclasses has not been investigated. Furthermore, the mechanisms by which walnuts improve lipid/lipoprotein concentrations are incompletely understood.
OBJECTIVES
We aimed to examine, as exploratory outcomes of this trial, the effect of replacing SFAs with unsaturated fats from walnuts or vegetable oils on lipoprotein subclasses, cholesterol efflux, and proprotein convertase subtilisin/kexin type 9 (PCSK9).
METHODS
A randomized, crossover, controlled-feeding study was conducted in individuals at risk of cardiovascular disease (CVD) (n = 34; 62% men; mean ± SD age 44 ± 10 y; BMI: 30.1 ± 4.9 kg/m2). After a 2-wk run-in diet (12% SFAs, 7% PUFAs, 12% MUFAs), subjects consumed the following diets, in randomized order, for 6 wk: 1) walnut diet (WD) [57-99 g/d walnuts, 7% SFAs, 16% PUFAs [2.7% α-linolenic acid (ALA)], 9% MUFAs]; 2) walnut fatty acid-matched diet [7% SFAs, 16% PUFAs (2.6% ALA), 9% MUFAs]; and 3) oleic acid replaces ALA diet (ORAD) [7% SFAs, 14% PUFAs (0.4% ALA); 12% MUFAs] (all percentages listed are of total kilocalories ). Serum collected after the run-in (baseline) and each diet period was analyzed for lipoprotein classes and subclasses (vertical auto profile), cholesterol efflux, and PCSK9. Linear mixed models were used for data analysis.
RESULTS
Compared with the ORAD, total cholesterol (mean ± SEM -8.9± 2.3 mg/dL; -5.1%; P < 0.001), non-HDL cholesterol (-7.4 ± 2.0 mg/dL; -5.4%; P = 0.001), and LDL cholesterol (-6.9 ± 1.9 mg/dL; -6.5%; P = 0.001) were lower after the WD; no other pairwise differences existed. There were no between-diet differences for HDL-cholesterol or LDL-cholesterol subclasses. Lipoprotein(a) [Lp(a)], cholesterol efflux, and PCSK9 were unchanged after the diets.
CONCLUSIONS
In individuals at risk of CVD, replacement of SFAs with unsaturated fats from walnuts or vegetable oils improved lipid/lipoprotein classes, including LDL-cholesterol, non-HDL cholesterol, and total cholesterol, without an increase in Lp(a). These improvements were not explained by changes in cholesterol efflux capacity or PCSK9. This trial was registered at clinicaltrials.gov as NCT01235832.
Identifiants
pubmed: 31909809
pii: S0022-3166(22)02120-4
doi: 10.1093/jn/nxz313
pmc: PMC7138686
doi:
Substances chimiques
Cholesterol, HDL
0
Cholesterol, LDL
0
Fats, Unsaturated
0
Fatty Acids
0
Lipoprotein(a)
0
Plant Oils
0
PCSK9 protein, human
EC 3.4.21.-
Proprotein Convertase 9
EC 3.4.21.-
Banques de données
ClinicalTrials.gov
['NCT01235832']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
818-825Subventions
Organisme : NCATS NIH HHS
ID : TL1 TR002016
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002014
Pays : United States
Informations de copyright
Copyright © The Author(s) 2020.
Références
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
J Am Coll Cardiol. 2013 Oct 22;62(17):1575-9
pubmed: 23973688
Nutr Rev. 2015 Jun;73(6):335-47
pubmed: 26011909
J Am Heart Assoc. 2019 May 7;8(9):e011512
pubmed: 31039663
Eur Heart J. 2010 Dec;31(23):2844-53
pubmed: 20965889
Am J Clin Nutr. 2007 Dec;86(6):1611-20
pubmed: 18065577
Am J Clin Nutr. 1999 Sep;70(3 Suppl):504S-511S
pubmed: 10479223
N Engl J Med. 2018 Nov 29;379(22):2097-2107
pubmed: 30403574
J Clin Lipidol. 2019 May - Jun;13(3):374-392
pubmed: 31147269
Circulation. 2017 Jul 18;136(3):e1-e23
pubmed: 28620111
Circulation. 2013 Jul 30;128(5):553-65
pubmed: 23897849
Clin Lab Med. 2006 Dec;26(4):787-802
pubmed: 17110240
Am J Clin Nutr. 2012 May;95(5):1003-12
pubmed: 22492369
J Lipid Res. 2016 Nov;57(11):1953-1975
pubmed: 27677946
PLoS One. 2014 Dec 15;9(12):e114859
pubmed: 25506933
Am J Clin Nutr. 2019 May 1;109(5):1239-1250
pubmed: 31051508
J Clin Lipidol. 2011 Sep-Oct;5(5):338-67
pubmed: 21981835
Arterioscler Thromb Vasc Biol. 1998 Mar;18(3):441-9
pubmed: 9514413
Clin Sci (Lond). 2015 Sep;129(5):439-46
pubmed: 25857271
Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):498-503
pubmed: 14739118
Lipids Health Dis. 2016 May 17;15:95
pubmed: 27184891
J Nutr. 2013 Jun;143(6):788-94
pubmed: 23616506
Nutr Metab (Lond). 2011 Aug 26;8:61
pubmed: 21871057
Am J Clin Nutr. 2018 Jul 1;108(1):174-187
pubmed: 29931130
J Nutr. 2018 Jun 1;148(6):861-867
pubmed: 29726951
Circulation. 2013 Sep 10;128(11):1256-67
pubmed: 24019446